

RECEIVED

JUN 2 5 2003





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Karen AKINSANYA et al.

Title:

LHRH ANALOGUES FOR THE TREATMENT

OF OSTEOPOROSIS

Appl. No.:

09/830,343

Filing Date:

04/26/2001

Examiner:

Olga CHERNYSHEV

TECH CENTER 1600/2900

Art Unit:

1646

TRANSMITTAL OF RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Sequence Listing mailed on May 21, 2003, in which a response is due to be filed on June 21, 2003, transmitted are:

- [X] Copy of PTO Notice to Comply.
- Amendment In Response To Notice to Comply with Requirements for [ X ] Sequence Listing directing its entry into the specification.
- [ X ] A statement that the content of the substitute paper and CRF are identical and, where applicable, include no new matter.
- [X] A paper copy of the Sequence Listing.
- [X] A computer readable form (CRF) copy of the Sequence Listing.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise

improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

**FOLEY & LARDNER** 

Customer Number: 22428

PATENT TRADEMARK OFFICE

Telephone:

(202) 672-5404

Facsimile:

(202) 672-5399

Stephen A. Bent Attorney for Applicants Registration No. 29,768

	TPE
	111 5 0 5003 12
/	Not
	TE TRADEME

## tice to Comply

Application No.	Applicant(s)
09/830,343	AKINSANYA ET AL.
Examiner	Art Unit
Olga N. Chernyshev	1646

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements

		37 C.F.R. 1.021 - 1.825 for the following reason(s):
	Ø	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
[	J	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
ם		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
. 2		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	] (	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	] 7	7. Other:
A	<b>p</b> p	plicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
		An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the cification.
nc	] A	A statement that the content of the paper and computer readable copies are the same and, where applicable, include ew matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

JUN 2 5 0003

Technical Assistance......703-287-0200 To Purchase Patentln Software.....703-306-2600

TECH CENTER 1600/2300

RECEIVE

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY